Clinically Relevant Drug Interactions with Monoamine Oxidase Inhibitors
Monoamine oxidase inhibitors (MAOI) are a class of drugs that were originally developed for the treatment of depression but have since been expanded to be used in management of affective and neurological disorders, as well as stroke and aging-related neurocognitive changes. Ranging from irreversible...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Open Medical Publishing
2022-11-01
|
| Series: | Health Psychology Research |
| Online Access: | https://doi.org/10.52965/001c.39576 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1825139387956985856 |
|---|---|
| author | Amber N. Edinoff Connor R. Swinford Amira S. Odisho Caroline R. Burroughs Cain W. Stark Walid A. Raslan Elyse M. Cornett Adam M. Kaye Alan D. Kaye |
| author_facet | Amber N. Edinoff Connor R. Swinford Amira S. Odisho Caroline R. Burroughs Cain W. Stark Walid A. Raslan Elyse M. Cornett Adam M. Kaye Alan D. Kaye |
| author_sort | Amber N. Edinoff |
| collection | DOAJ |
| description | Monoamine oxidase inhibitors (MAOI) are a class of drugs that were originally developed for the treatment of depression but have since been expanded to be used in management of affective and neurological disorders, as well as stroke and aging-related neurocognitive changes. Ranging from irreversible to reversible and selective to non-selective, these drugs target the monoamine oxidase (MAO) enzyme and prevent the oxidative deamination of various monoamines and catecholamines such as serotonin and dopamine, respectively. Tyramine is a potent releaser of norepinephrine (NE) and is found in high concentrations in foods such as aged cheeses and meats. Under normal conditions, NE is unable to accumulate to toxic levels due to the presence of MAO-A, an enzyme that degrades neurotransmitters, including NE. When MAO-A is inhibited, the capacity to handle tyramine intake from the diet is significantly reduced causing the brain to be vulnerable to overstimulation of postsynaptic adrenergic receptors with as little as 8-10 mg of tyramine ingested and can result in life-threatening blood pressure elevations. In addition to adverse reactions with certain foods, both older and newer MAOIs can negatively interact with both sympathomimetic and serotonergic drugs. In general, patients on a MAOI want to avoid two types of medications: those that can elevate blood pressure via sympathomimetic actions (e.g., phenylephrine and oxymetazoline) and those that can increase serotonin levels via 5-HT reuptake inhibition (e.g., dextromethorphan, chlorpheniramine, and brompheniramine). Illicit drugs that stimulate the central nervous system such as ecstasy (MDMA, 3,4-methylenedioxymethamphetamine) act as serotonin releasers. Patient involvement is also crucial to ensure any interaction within the healthcare setting includes making other providers aware of a MAOI prescription as well as avoiding certain OTC medications that can interact adversely with MAOIs. |
| format | Article |
| id | doaj-art-86ddca531f014807bdca08b1c5c6738a |
| institution | Kabale University |
| issn | 2420-8124 |
| language | English |
| publishDate | 2022-11-01 |
| publisher | Open Medical Publishing |
| record_format | Article |
| series | Health Psychology Research |
| spelling | doaj-art-86ddca531f014807bdca08b1c5c6738a2025-02-11T20:30:32ZengOpen Medical PublishingHealth Psychology Research2420-81242022-11-01104Clinically Relevant Drug Interactions with Monoamine Oxidase InhibitorsAmber N. EdinoffConnor R. SwinfordAmira S. OdishoCaroline R. BurroughsCain W. StarkWalid A. RaslanElyse M. CornettAdam M. KayeAlan D. KayeMonoamine oxidase inhibitors (MAOI) are a class of drugs that were originally developed for the treatment of depression but have since been expanded to be used in management of affective and neurological disorders, as well as stroke and aging-related neurocognitive changes. Ranging from irreversible to reversible and selective to non-selective, these drugs target the monoamine oxidase (MAO) enzyme and prevent the oxidative deamination of various monoamines and catecholamines such as serotonin and dopamine, respectively. Tyramine is a potent releaser of norepinephrine (NE) and is found in high concentrations in foods such as aged cheeses and meats. Under normal conditions, NE is unable to accumulate to toxic levels due to the presence of MAO-A, an enzyme that degrades neurotransmitters, including NE. When MAO-A is inhibited, the capacity to handle tyramine intake from the diet is significantly reduced causing the brain to be vulnerable to overstimulation of postsynaptic adrenergic receptors with as little as 8-10 mg of tyramine ingested and can result in life-threatening blood pressure elevations. In addition to adverse reactions with certain foods, both older and newer MAOIs can negatively interact with both sympathomimetic and serotonergic drugs. In general, patients on a MAOI want to avoid two types of medications: those that can elevate blood pressure via sympathomimetic actions (e.g., phenylephrine and oxymetazoline) and those that can increase serotonin levels via 5-HT reuptake inhibition (e.g., dextromethorphan, chlorpheniramine, and brompheniramine). Illicit drugs that stimulate the central nervous system such as ecstasy (MDMA, 3,4-methylenedioxymethamphetamine) act as serotonin releasers. Patient involvement is also crucial to ensure any interaction within the healthcare setting includes making other providers aware of a MAOI prescription as well as avoiding certain OTC medications that can interact adversely with MAOIs.https://doi.org/10.52965/001c.39576 |
| spellingShingle | Amber N. Edinoff Connor R. Swinford Amira S. Odisho Caroline R. Burroughs Cain W. Stark Walid A. Raslan Elyse M. Cornett Adam M. Kaye Alan D. Kaye Clinically Relevant Drug Interactions with Monoamine Oxidase Inhibitors Health Psychology Research |
| title | Clinically Relevant Drug Interactions with Monoamine Oxidase Inhibitors |
| title_full | Clinically Relevant Drug Interactions with Monoamine Oxidase Inhibitors |
| title_fullStr | Clinically Relevant Drug Interactions with Monoamine Oxidase Inhibitors |
| title_full_unstemmed | Clinically Relevant Drug Interactions with Monoamine Oxidase Inhibitors |
| title_short | Clinically Relevant Drug Interactions with Monoamine Oxidase Inhibitors |
| title_sort | clinically relevant drug interactions with monoamine oxidase inhibitors |
| url | https://doi.org/10.52965/001c.39576 |
| work_keys_str_mv | AT ambernedinoff clinicallyrelevantdruginteractionswithmonoamineoxidaseinhibitors AT connorrswinford clinicallyrelevantdruginteractionswithmonoamineoxidaseinhibitors AT amirasodisho clinicallyrelevantdruginteractionswithmonoamineoxidaseinhibitors AT carolinerburroughs clinicallyrelevantdruginteractionswithmonoamineoxidaseinhibitors AT cainwstark clinicallyrelevantdruginteractionswithmonoamineoxidaseinhibitors AT walidaraslan clinicallyrelevantdruginteractionswithmonoamineoxidaseinhibitors AT elysemcornett clinicallyrelevantdruginteractionswithmonoamineoxidaseinhibitors AT adammkaye clinicallyrelevantdruginteractionswithmonoamineoxidaseinhibitors AT alandkaye clinicallyrelevantdruginteractionswithmonoamineoxidaseinhibitors |